Update shared on31 Aug 2025
Fair value Increased 3.19%The notable increase in Everest Medicines’ consensus price target reflects a significant improvement in net profit margin alongside a sharp decline in future P/E, indicating enhanced profitability and a more attractive valuation, with the target rising to HK$57.29.
What's in the News
- The board will meet to discuss interim results for the first half of 2025 and other business.
- A 91-day lock-up period for certain ordinary shares will be in effect from August to October 2025 per agreement with placement agents.
- Everest Medicines completed a follow-on equity offering of 22,561,000 ordinary shares, raising HKD 1.57 billion at HKD 69.7 per share via subsequent direct listing.
- Positive preliminary Phase 1b/2a clinical trial results for EVER001 (BTK inhibitor) in primary membranous nephropathy showed the treatment was well-tolerated and effective; Everest holds global rights and is conducting the study in China.
Valuation Changes
Summary of Valuation Changes for Everest Medicines
- The Consensus Analyst Price Target has risen slightly from HK$55.53 to HK$57.29.
- The Net Profit Margin for Everest Medicines has significantly risen from 13.56% to 21.02%.
- The Future P/E for Everest Medicines has significantly fallen from 46.99x to 28.54x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.